SGN-B6A
- Generic Name
- SGN-B6A
- Drug Type
- Biotech
- Background
SGN-B6A is a humanized immunoglobulin G1 anti-integrin beta-6 monoclonal antibody conjugated to monomethyl auristatin E.
This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.
- Conditions
- Non-Small Cell Lung CancerCarcinoma, Non-Small-Cell LungCarcinoma, Non-Small-Cell Lung (NSCLC)
- Interventions
- First Posted Date
- 2025-01-03
- Last Posted Date
- 2025-05-14
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 714
- Registration Number
- NCT06758401
- Locations
- 🇺🇸
Mid Florida Hematology and Oncology Center, Orange City, Florida, United States
🇺🇸BRCR Global, Plantation, Florida, United States
🇺🇸Hope and Healing Cancer Services, New Lenox, Illinois, United States
A Study of SGN-B6A in Chinese Participants With Advanced Solid Tumors
- Conditions
- Esophageal Squamous Cell CarcinomaGastroesophageal Junction AdenocarcinomaSquamous Cell Carcinoma of Head and NeckEsophageal AdenocarcinomaGastric AdenocarcinomaCarcinoma, Non-Small Cell Lung
- Interventions
- First Posted Date
- 2024-08-12
- Last Posted Date
- 2025-05-14
- Lead Sponsor
- Seagen, a wholly owned subsidiary of Pfizer
- Target Recruit Count
- 6
- Registration Number
- NCT06549816
- Locations
- 🇨🇳
Jiangsu Province Hospital, Nanjing, Jiangsu, China
🇨🇳Guangdong Provincial People's Hospital, Guangzhou, Guangdong, China
🇨🇳Union Hospital Affiliated to Tongji Medical College,Huazhong University of science and Technology, Wuhan City, Hubei, China
A Study of Sigvotatug Vedotin Versus Docetaxel in Previously Treated Non-small Cell Lung Cancer
- Conditions
- Carcinoma, Non-Small-Cell Lung
- Interventions
- First Posted Date
- 2023-08-25
- Last Posted Date
- 2025-05-13
- Lead Sponsor
- Seagen, a wholly owned subsidiary of Pfizer
- Target Recruit Count
- 670
- Registration Number
- NCT06012435
- Locations
- 🇨🇭
Inselspital, Bern, Other, Switzerland
🇫🇷Hospital Center De Cornouaille, Quimper Cedex, Other, France
🇫🇷Centre Hospitalier Universitaire de Rennes, Hopital Pontchaillou, Rennes, Other, France
A Study of SGN-B6A in Advanced Solid Tumors
- Conditions
- Squamous Cell Carcinoma of Head and NeckHER2 Negative Breast NeoplasmsCutaneous Squamous Cell CancerExocrine Pancreatic AdenocarcinomaUterine Cervical NeoplasmsCarcinoma, Non-Small Cell LungEsophageal Squamous Cell CarcinomaUrinary Bladder NeoplasmsEsophageal AdenocarcinomaGastroesophageal Junction Adenocarcinoma
- Interventions
- First Posted Date
- 2020-05-15
- Last Posted Date
- 2025-05-13
- Lead Sponsor
- Seagen, a wholly owned subsidiary of Pfizer
- Target Recruit Count
- 1006
- Registration Number
- NCT04389632
- Locations
- 🇺🇸
US Oncology Investigational Product Center (IPC), Irving, Texas, United States
🇺🇸Houston Medical Imaging, Pearland, Texas, United States
🇺🇸Alaska Oncology and Hematology, Anchorage, Alaska, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.